The Avita Medical Inc (ASX: AVH) share price is flying high on Friday. At the time of writing, shares in the medical technology business are swapping hands for $5.11 – up 13.56%.

This comes after the company announced it had received approval from the US Food and Drug Administration (FDA) to expand the use of its skin-grafting technology.

Let’s take a closer look at today’s news.

FDA approval

Avita shares are having a bumper day after the dual-listed company provided a statement to the ASX this morning. Avita advised the FDA has provided approval for the “expanded use of the RECELL System, in combination with meshed autografting,” for children over 1 month of age. Until now, the system had only be approved for use on adults.

On top of this, the US Government agency says the treatment can be used for full-thickness thermal wounds that cover more than half the body.

According to Avita, RECELL is used to prepare spray-on skin cells for application on the patient while requiring “significantly” less donor skin. In addition, the company claims a skin sample as small as a credit card can be used to treat an adult’s entire back.

Today’s release quoted Dr Anjay Khandelwal of Akron Children’s Hospital Burn Center, Ohio as saying:

Skin grafting, which is currently the standard of care used to treat many paediatric burns, is painful, results in an additional wound, can be disfiguring, and may result in additional complications as a child grows.

… I am pleased that the RECELL System, with its proven efficacy to accelerate the burn-healing process with less donor skin requirements, is now available as an FDA-approved treatment option for my younger burn patients.

As well, Avita stated that “nearly a quarter of the burn cases in the United States occur in children under the age of 16 years old.”

Investors appear to believe this is good news for the company, judging by the performance of the Avita share price so far today.

The product is registered with the Therapeutics Good Administration in Australia and received CE-mark approval in Europe.

Management commentary

Avita Medical CEO Dr Mike Perry said of today’s news:

We are pleased that the RECELL System, with both its clinical and health economic benefits, can now more broadly support surgeons in treating full-thickness burns of all sizes, including treatment of patients over 1 month of age.

… the RECELL System is rapidly becoming the standard of care in burn treatment, and we are committed to pursuing and realising the full potential of this innovative regenerative technology platform to address other clinical indications where significant unmet need exists.

Avita share price snapshot

Over the past 12 months, Avita shares have fallen by more than 40%. This stands in stark contrast to many ASX businesses, which have seen their value grow significantly since the COVID-19 market crash of March 2020.

However, in more positive news, today’s rally now sees the Avita share price up by 3.44% in 2021.

The post Why the Avita Medical (ASX:AVH) share price is soaring 14% appeared first on The Motley Fool Australia.

More reading

• ASX 200 rebounds, Treasury rises, Xero falls
• Why the AVITA (ASX:AVH) share price is charging higher today

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Avita Medical Limited. The Motley Fool Australia has recommended Avita Medical Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3iFHs82

The BlueScope Steel Limited (ASX: BSL) share price is getting a boost from a broker upgrade this morning.

The steel products manufacturer’s share price jumped 1.8% at the time of writing to $22.53. In contrast, the S&P/ASX 200 Index (Index:^AXJO) is struggling at around breakeven.

The outperformance of the BlueScope share price coincides with Macquarie Group Ltd’s (ASX: MQG) decision to lift its rating on the shares to “outperform” from “neutral”.

Good spreads drive BlueScope share price upgrade

The broker’s bullish turn comes as its analysts took a more upbeat view on steels spreads, or margins.

“Our Macro Strategy team has upgraded the outlook for the steel complex,” said Macquarie.

“Spread expectations expand, especially in 1HFY22 in the US, driving earnings upgrades. The team still expect a roll-over in prices when IP [industrial production] slows, but reduced China export suggests structurally better margins.”

Positive outlook for US steel

Steel in the US have continued to rally and the benchmark prices are trading more than US$200 a ton above their levels on 27 April. That was when BlueScope last provided guidance for the second half of FY21.

Macquarie believes that steel prices will hold on to these gains into the September quarter. But prices are then expected to moderate along a more benign curve than previously expected.

Lumber shortage gives boost in Australia

Meanwhile, the outlook for Australian steel prices also remain constructive thanks to the booming housing market.

“Builders continue to report solid demand even after HomeBuilder, which should support broad demand,” said Macquarie.

“Lumber shortages are also playing into steel demand – although BSL would also likely be constrained for capacity in this niche product.”

Cashed up to capitalise on opportunities

BlueScope’s growing cash pile will give management options too. While the company is still running an on-market share buyback program, Macquarie thinks it will be hesitant to purchase shares at current prices.

If so, this will give BlueScope the flexibility to undertake other forms of capital return or even use its cash balance to make a bolt-on acquisition, in my view.

What is the BlueScope share price worth?

“While we remain vigilant that falling steel prices could impact the stock – and present the most significant risk to our view – we think EPS momentum is likely to remain very strong in the near term,” added Macquarie.

“Underpinned by a revised house view on the steel complex and valuation that remains attractive (NTM EV/EBIT at 12% discount to 5-year avg), there is a better risk-reward balance now.”

Macquarie’s 12-month price target on the BlueScope share price is $25.50 a share.

The post BlueScope (ASX:BSL) share price jumps on broker upgrade today appeared first on The Motley Fool Australia.

More reading

• These ASX shares just got hit by broker downgrades
• 2 high-quality ASX 200 shares that could be buys
• 5 things to watch on the ASX 200 on Friday
• ASX 200 rises, Woolworths acquisition approved, Austal in rough waters
• The ASX shares benefiting the most from the company spending boom

Brendon Lau owns shares of BlueScope Steel Limited and Macquarie Group Ltd. Follow me on Twitter @brenlau.

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3gaP54L

ASX healthcare shares didn’t, as a whole, have the best of years in 2020.

In fact, Randal Jenneke – head of Australian equities at the US investment firm T Rowe Price – says healthcare just suffered through its worst year in a decade.

But he believes that’s all turning around.

And in the hunt for what Jenneke labels “quality growth” stocks, ASX healthcare shares are under the microscope.

Leading ASX healthcare share “really attractive”

According to Jenneke (quoted by the Australian Financial Review):

That’s where we see good opportunity. ResMed is an example of a stock that we think is really attractive. Valuations are back to the most attractive level in five years. As the US economy reopens, the sleep business can get back to normal and there’s a new product cycle coming.

If you’re not familiar with the company, ResMed CDI (ASX: RMD) is a leading S&P/ASX 200 Index (ASX: XJO) healthcare share.

Its primary business is developing respiratory medical devices, with a focus on the treatment of sleep apnoea. During the height of the COVID epidemic, ResMed also turned its attention to the production of respirators.

Based in the US state of California, the ASX healthcare share operates in more than 140 countries. It has manufacturing facilities in Australia, Singapore, France, and the US.

ResMed first listed on the ASX in November 1999, trading for less than $1 per share. Today it has a market cap of $41 billion.

ResMed share price snapshot

Over the past 12 months the ResMed share price has gained 19%, trailing the 22% gains posted by the ASX 200 over that same time.

Year-to-date the ASX health care share has gained 3.2% and is currently trading at $28.47 per share.

ResMed also pays a smallish dividend yield of 0.5%, unfranked.

The post Blue chip ASX healthcare share “really attractive”: top analyst appeared first on The Motley Fool Australia.

More reading

• What I regret about my Afterpay (ASX:APT) shares: analyst
• Is the ResMed (ASX:RMD) share price good value?
• 5 things to watch on the ASX 200 on Wednesday
• 3 highly rated ASX growth shares analysts love
• 2 blue chip ASX shares rated as buys

Bernd Struben does not own any shares mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3zgVtiD

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

What happened

Shares of coronavirus vaccine maker Novavax (NASDAQ: NVAX) tanked by 37.7% in May, according to data provided by S&P Global Market Intelligence. The collapse was a result of the company’s repeated delays with the manufacturing of its coronavirus vaccine as well as its announcement that it won’t file for the candidate’s regulatory approval before the third quarter.

So what

The combination of delays with regulatory filings and manufacturing delays means that Novavax won’t be able to deliver its contractually obligated doses to the European Union before 2022. In short, certain raw materials needed for the vaccine are in scant supply. Furthermore, the company will be even further behind other vaccine makers like Pfizer and Moderna, which are already on the market and in wide distribution.

In the long run, however, these issues probably won’t harm the company’s revenue making potential. Even amid the delays, Novavax is still signing new sales agreements with groups like the Gavi Vaccine Alliance, which agreed to buy 350 million doses of its vaccine on May 6. Likewise, Novavax still has commitments to make more than 1.1 billion doses in conjunction with its manufacturing collaborators. So, while May’s losses might be frustrating, they probably don’t reflect much genuine destruction of shareholder value. It’s likely that the stock will rebound once sales revenue starts to be reflected in earnings reports.

Now what

While investors are unlikely to have much patience for further delays, Novavax is still proceeding with its plans to commercialize its coronavirus vaccine globally, and it will almost certainly continue to succeed in doing so. Notably, in early May it also reported that its candidate is effective against at least one viral variant, which should keep it competitive with the currently marketed vaccines. But shareholders will need to wait a bit longer before the full impact of the revenue is reflected in the company’s quarterly earnings reports.

Beyond that, the company is also pursuing its combination vaccine project, which could inoculate people against both influenza and the coronavirus in a single jab. On May 10, it published preliminary evidence from preclinical studies that suggests the combination vaccine could be effective.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The post Why shares of Novavax crashed 37.7% in May appeared first on The Motley Fool Australia.

More reading

• Why the Premier Investments (ASX:PMV) share price just hit a record high
• The Imugene (ASX:IMU) share price has fallen 14% in the last 5 days
• Why the Fatfish (ASX:FFG) share price is rocketing 38% higher today
• Here’s why the Syrah (ASX:SYR) share price is pushing higher today
• Moderna files for FDA approval of its COVID vaccine in teens

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

from The Motley Fool Australia https://ift.tt/3cwDElG

The Premier Investments Limited (ASX: PMV) share price popped into record territory this morning after the company provided a 2H21 and FY21 trading update.

In early morning trade, the company’s share price jumped by 5.2% to hit a new, all-time high of $28.75. However, at the time of writing, Premier shares have retreated back to $27.37, 0.15% higher for the day so far.

Let’s take a look at the latest news from Premier.

Trading update

The Premier share price received a boost this morning after the company announced its strong trading momentum has continued into the second half of FY21.

Premier advised that total global sales for the first 18 weeks of 2H21 ended 5 June 2021 had surged 70% against the comparable period in 2H20 and was up 15.8% against the comparable 18 weeks of 2H19.

The group’s upbeat trading result was driven by a particularly strong performance during the “all-important” Easter School Holiday period, alongside a record Mother’s Day and May result.

Looking ahead, the company expects FY21 earnings before interest and tax (EBIT) to be in the range of $340 million and $360 million. This represents an increase of between 82% and 92% against FY20 EBIT and between 103% and 115% against FY19 EBIT.

Premier points to strong customer demand for its winter product range across all brands, continued strength in online sales and margin expansion as key drivers of its anticipated record FY21 EBIT.

It is worth taking into account that the forecasted record FY21 result comes with the assumption that retail trading conditions remain strong, with no further COVID-19-related store closures or mobility restrictions that could influence consumer shopping decisions.

Management commentary

Premier Investments executive director and CEO Mr Mark McInnes commented on the strong results:

Today’s FY21 EBIT upgraded range will represent another record result for Premier’s shareholders. The strategic decision taken last year by the Chairman and I to build our supply chain and significantly invest in wanted inventory for Easter, April school holidays, Mother’s Day and the winter season has ensured we are in stock, delivering strong sales and gross margin growth across all our brands.

The Group has successfully enabled customers to shop seamlessly either online or in-store during the COVID-19 health crisis. This has been achieved through the long term strategic investments made in our online capability combined with our ability to reach mutual agreements with landlords to appropriately rebase rents.

Premier Investments share price snapshot

Premier Investments has released several upbeat trading announcements this year, which were followed by a pop in its share price.

On 13 January, the company released a positive 1H21 trading update that saw the Premier share price shoot as much as ~18% higher to $26.70.

Premier Investments shares jumped again on 24 March, following the release of the company’s half-year results. The shares opened 8% higher on the day to $25.85 before closing 4.65% higher at $24.94.

Similarly, investors have responded positively to today’s trading update, sending Premier shares into record territory.

The post Why the Premier Investments (ASX:PMV) share price just hit a record high appeared first on The Motley Fool Australia.

More reading

• 2 ASX 200 shares that could be reliable picks for dividends
• Retail sales rose 1.1% in April, but some ASX retail shares are selling off in May
• 2 ASX 200 shares to buy for growth

Motley Fool contributor Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Premier Investments Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3vcMRGC

Shares in Imugene Limited (ASX: IMU) continue to be among the most traded shares on the market. Unfortunately for investors, the Immugene share price has been on a heavy losing streak this week, falling 14% in the last 5 days.

Imugene is a clinical stage immuno-oncology company currently developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours.

The company is conducting a number of trials including HER-Vaxx, an immunotherapy to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

The Imugene share price has been volatile recently, rising from 12 cents in April to a record high of 50 cents at the end of May, more than tripling its value.

June has brought a change in fortune, however, with shares sliding back to their current price of 32.5 cents apiece. With no negative announcements from the company, let’s take a look at what’s been happening recently.

Recent announcements

Since April, the company has released several announcements that have sent the Imugene share price surging higher.

One significant release came on 21 April when Imugene announced that the second clinical endpoint for its HER-Vaxx clinical studies had been met.

On 18 May, Imugene declared it had entered into an agreement with City of Hope, an independent cancer research and treatment centre, to license the patent for its CD19 therapy.

It was a world first, with the technology under the license being an extension of chimeric antigen receptor (CAR) T cell cancer therapy, which has the potential to treat solid cancers. Imugene plans to begin its first clinical trial of CD19 in 2022.

Following that announcement, banking firm FROTH Capital raised the Immugene share price target to 42 cents. This was based on a number of factors, including the projected future revenue of Imugene CHECKvacc, HER-Vaxx, and PD1-Vaxx trials.

With the biotech’s surging share price a likely reflection of its significant announcements in the world of immunology, the latest price drop is a bit of a mystery. It’s possible there could be some profit-selling at play.

The good news today is the Imugene share price is lifting again, up 3.8% trading at 32.5 cents at the time of writing.

The post The Imugene (ASX:IMU) share price has fallen 14% in the last 5 days appeared first on The Motley Fool Australia.

More reading

• These 3 ASX 200 shares are the most actively traded today
• These 3 ASX 200 shares were among the biggest movers today
• Why A2 Milk, ASX Ltd, Galaxy, & Imugene shares are dropping today
• Imugene and Zip were among the most traded ASX shares last week
• Why the Imugene (ASX:IMU) share price is up 13% to a record high

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3gd91nS

The Fatfish Group Ltd (ASX: FFG) share price has returned from its week-long suspension with a bang.

In early trade, the technology venture company’s shares were up as much as 38% to 10.5 cents.

The Fatfish share price has since eased back but remains up 18.5% to 9 cents at the time of writing.

Why is the Fatfish share price zooming higher?

The Fatfish share price is zooming higher today after the company announced an agreement to acquire BNPL Next for a consideration of A$4.14 million.

The release explains that BNPL Next is a holding company that aims to provide various corporate and consumer financial services in the South East Asia market.

The company also owns a 60% interest in Circopay, which is an Earned Wage Access (EWA) solutions provider allowing employees early access to earned wages. It has raised just over A$1million in funding and secured credit lines of A$5 million to facilitate its EWA services.

Management notes that the Circopay business is in an early growth phase and therefore it is not able to quantify the revenue income for Fatfish as a proposed 60% shareholder. If and when the revenue impact of the Circopay business can be responsibly determined, Fatfish will make further disclosure to the market at that time.

Why acquire BNPL Next?

According to the release, management believes the acquisition of BNPL Next fits into its strategy to invest in and build on emerging global technology trends in digital financing needs. This is especially the case given its existing plan to roll out buy now pay later (BNPL) services across Southeast Asia.

In addition to this, it believes the EWA market is an attractive place to be. This is due to its “win-win nature for both employees and employers.”

Another positive it sees from the deal is the first-mover advantage it gives the company. It notes that as one of the pioneer EWA service providers in Southeast Asia (where a large proportion of the working population have comparatively lower income as well as limited access to financial services), Circopay is poised to capitalise on its first-mover advantage within the region.

Despite today’s strong gain, the Fatfish is down a whopping 79% from its 52-week high.

The post Why the Fatfish (ASX:FFG) share price is rocketing 38% higher today appeared first on The Motley Fool Australia.

More reading

• Fatfish (ASX:FFG) shares in trading halt pending BNPL acquisition

James Mickleboro does not own any shares mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3g9RzjU

The Syrah Resources Ltd (ASX: SYR) share price is pushing higher on Friday morning.

At the time of writing, the graphite producer’s shares are up 2% to $1.08.

Why is the Syrah share price pushing higher?

Investors have been bidding the Syrah share price higher today after it announced its decision to issue a $28 million (US$22 million) convertible note tranche to AustralianSuper.

This follows the signing of an agreement in December with the super fund, which gave Syrah the option issue convertible notes totalling A$56 million (US$43 million) in two tranches.

While the first $28 million (US$22 million) tranche was not issued earlier this year due to its strong balance sheet position, the second tranche has been issued to support the orderly ramp-up of production at Balama under various market scenarios.

The funds will also be used to maintain project momentum for the proposed expansion of production capacity at its Active Anode Material Facility in Vidalia, USA.

Market conditions improve

The release explains that electric vehicle, anode material and natural graphite market conditions are constructive. This is supporting the ramp-up of production at Balama towards an initial target of 15kt per month.

Though, it stressed that it is continuing to be disciplined in its ramp-up at Balama by considering market demand and leading indicators.

Over in the United States, the Initial Detailed Design for the expansion of production capacity at Vidalia has improved the definition of costs in the Bankable Feasibility Study (BFS). Pleasingly, the estimated capital costs for the construction of a 10ktpa AAM facility at Vidalia remain consistent with the BFS, with the full proposed contingency being maintained.

Syrah’s cash position as at 30 June 2021, which will include proceeds from the note issue, is expected to be US$81 million.

The post Here’s why the Syrah (ASX:SYR) share price is pushing higher today appeared first on The Motley Fool Australia.

More reading

• Short sellers who sledge ASX companies put on notice
• Syrah (ASX:SYR) share price edges higher on positive update

James Mickleboro does not own any shares mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3pFcgYi

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

On Thursday, Moderna (NASDAQ: MRNA) announced it has filed for Emergency Use Authorization for its COVID-19 vaccine in adolescents from 12 to 18. If the agency gives Moderna a green light, parents will have another vaccine option beyond Pfizer (NYSE: PFE) and BioNTech‘s (NASDAQ: BNTX) vaccine, which was approved for ages 12 to 18 in May.

The coronavirus can be spread easily, and so far, over 174 million cases and 3.7 million deaths have been attributed to the disease worldwide.

Drugmakers including Moderna have developed vaccines to help prevent severe disease, and over the past few months, governments have made significant progress in vaccinating adult populations. For example, over 304 million COVID vaccine doses have been administered in the U.S., with 52% of Americans having received at least one dose.

The vaccination rate in children is lower, with only 23% of Americans under 18 having received at least one dose, but that rate should improve as more vaccines secure FDA approval. The agency expanded emergency use of Pfizer’s COVID vaccine to include children over 12 last month, and a meeting of its advisory committee to discuss vaccinating adolescents is happening this week. 

Investigators observed no COVID cases in Moderna’s study of patients ages 12 to 18, and safety outcomes were similar to those for adults, suggesting the vaccine could win emergency approval soon.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The post Moderna files for FDA approval of its COVID vaccine in teens appeared first on The Motley Fool Australia.

More reading

• Here’s how Moderna plans to beat the biggest threat to its vaccine
• Moderna’s teen COVID-19 vaccine trial hits high marks
• CSL (ASX:CSL) share price backtracks despite renewed optimism
• Australia eyes Moderna (NASDAQ:MRNA) COVID-19 vaccine delivery
• What the Federal Budget could mean for CSL (ASX:CSL) shares

Todd Campbell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

from The Motley Fool Australia https://ift.tt/2TdKDcB

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Investing in digital currencies, especially in the extremely hot coins, requires a little bit of industry knowledge and a whole lot of DYOR-ing. Luckily, once you’ve mastered both, you can be on your way to making more thoughtful — and potentially lucrative — decisions in cryptocurrency investments.

With the current crypto market cap looking at an eye-popping $1.5 trillion, and over 10,000 coins to choose from, more and more investors are adding digital currencies to their portfolios. As a result, the days of holding only the Big Two, Bitcoin (CRYPTO: BTC) and Ethereum (CRYPTO: ETH) are, quite frankly, passé.

In the hope that they’ll strike gold by pulling the trigger on the newest trending altcoin (any coin that is not Bitcoin), many investors rush in, chasing the pump. While I appreciate that new crypto investors are eager and sometimes overly confident, I do believe in being conservative.

That is until you know what you are doing and how you limit your losses. With this in mind, let’s take a deep dive into the trusted hacks that measure any altcoin’s stability. 

The 7 crypto golden rules

Go to the DEX (decentralized exchange) of your choice, and search for coins that have been on your radar. Keep all options open. Otherwise, you might miss out on some real gems. Don’t follow the market. Follow the numbers.

Then, click on your selections, follow these steps, and compare each coin side by side as if your life (rather, your wallet) depends on it.

And remember, don’t chase the pump!

1. Research: Be wary of the news and coins that are being shilled on Reddit as well as social media. When investigating a coin, see what kind of project it is supporting and if there is good value behind it. In other words-is it just another “memecoin” or is it attached to something innovative? Even better-join the coin’s Telegram channel and see what people are generally saying about the coin itself.
2. Volume: Click on the Volume tab as your primary filter. The highest volume coins are moving the fastest at low opportunity costs. This reduces the chances of getting trapped in a pump-and-dump.
3. Percentage change: Check out the moving average indicator line. If you see a sudden, sharp drop from a coin’s all-time high, you don’t want to invest in it, because this coin has already broken its upswing trend and you risk losing money.
4. If it’s a solid uptrend: It’s ok to buy high and sell higher, especially in a bull market.
5. Market cap: Although not a deal breaker, it’s nice to see that a coin has a high market cap. The higher the market cap, the more people have invested in this particular coin. Therefore, comparing all your coins here is always a good idea.
6. Circulating supply: If this is an infinite number, you’re in trouble. This coin will go nowhere in value and fast. On the other hand, a healthy coin should have an excellent circulating supply in the multi-millions and beyond. 
7. TVL (Total Value Locked): Simply put, TVL shows that there is enough money locked into a coin to initiate its actual launch. This is an actual funding pool that lenders deposit money into. It shows exactly how much risk has gone into a coin. In fact, I would worry if a coin’s TVL was under $1 million (for a new coin) and under $300 million for an established coin. But again-the higher the better.

And that’s pretty much it!

Once you get the hang of things, you’ll be able to invest like a crypto expert. Always remember to investigate and compare all options. Did coin #1 not meet any of the 7 rules? Run for the hills. Ask yourself if you really want to get in. Did coin #3 check all the boxes? Great! Just remember to always research the heck out of each option, make sure it serves a legitimate purpose, and avoid falling for coins that promise to go “to the moon!” 

We all know what happened with that last one.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The post 7 golden rules for crushing your crypto investments appeared first on The Motley Fool Australia.

More reading

• In a world first, El Salvador makes Bitcoin legal tender
• How Aussies raked in $260 million in Bitcoin profits in 2020
• Bitcoin stocks tumble after authorities recover ransom paid by Colonial Pipeline
• Bitcoin slammed as “least favourite asset for investment”
• Could this be the first country to adopt Bitcoin as legal tender?

Isabelle Korman owns Bitcoin and Ethereum. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Bitcoin. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

from The Motley Fool Australia https://ift.tt/3wk53iY